Olema Pharmaceuticals (OLMA) Retained Earnings (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Retained Earnings data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Retained Earnings rose 33.36% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 33.36% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 347.18% from the prior year.
• Retained Earnings for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
• Over the last five years, Retained Earnings for OLMA reached as high as $1.1 billion in Q1 2026 and fell as low as -$509.3 million in Q2 2025.
• Historically, Retained Earnings has averaged $257.0 million across 5 years, with a median of $393.9 million in 2022.
• Across the five-year window, Retained Earnings soared 2848357.14% in 2022 and sank 125490.78% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$209.0 million in 2022, then soared by 100.17% to $347000.0 in 2023, then sank by 125490.78% to -$435.1 million in 2024, then soared by 347.18% to $1.1 billion in 2025, then grew by 5.22% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $858.5 million in Q3 2025.